

Cardiovascular Systems Inc  
Form 8-K  
March 29, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2018  
Cardiovascular Systems, Inc.  
(Exact name of Registrant as Specified in its Charter)

Delaware                                      000-52082      41-1698056  
(State or Other Jurisdiction   (Commission   (IRS Employer  
of Incorporation)                      File Number)   Identification No.)

1225 Old Highway 8 Northwest  
St. Paul, Minnesota 55112-6416

(Address of Principal Executive Offices and Zip Code)

(651) 259-1600

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01. Other Events.

## Edgar Filing: Cardiovascular Systems Inc - Form 8-K

On March 23, 2018, the independent members of the Board of Directors of Cardiovascular Systems, Inc. (the “Company”) approved a waiver of the conflict of interest provisions of the Company’s Code of Ethics and Business Conduct with respect to the provision of certain laboratory support services to TVA Medical, Inc. (“TVA”) by the Company. Dr. William Cohn, a member of the Company’s Board of Directors, is also a director and stockholder of TVA, a development stage company. TVA will pay CSI fair market value rates for these services, which are expected to be less than \$12,000 in the aggregate. Dr. Cohn and Scott Ward, the Company’s Chairman, Chief Executive Officer and President, did not participate in such vote. Dr. Cohn will recuse himself on both the Company and TVA boards with respect to any issues that involve both the Company and TVA.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 29, 2018

CARDIOVASCULAR  
SYSTEMS, INC.

By: /s/ Jeffrey Points

Jeffrey Points

Chief Financial Officer